Short Interest Update on Pernix Therapeutics Holdings (PTX)

Pernix Therapeutics Holdings (PTX) : 1 days before expiry, shorts in Pernix Therapeutics Holdings (PTX) have reduced from 5,565,393 on Jul 29, 2016, to 5,459,749 on August 15, 2016. On an average, 10,175,954 shares are traded on the exchange. The outstanding bearish positions are equal to 11.1% of the float. Short sellers have covered -105,644 shares, a reduction of -1.9%, which underlines that they dont expect the stock to fall further from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.

Pernix Therapeutics Holdings (NASDAQ:PTX): The stock opened at $0.77 on Wednesday but the bulls could not build on the opening and the stock topped out at $0.78 for the day. The stock traded down to $0.71 during the day, due to lack of any buying support eventually closed down at $0.72 with a loss of -4.62% for the day. The stock had closed at $0.76 on the previous day. The total traded volume was 4,757,111 shares.


In a related news, Siegel Barry J, officer (Senior VP and General Counsel) of Pernix Therapeutics Holdings, Inc. had purchased 5,000 shares on August 19, 2015 in a transaction. The price per share was $4.49 and the total amount of the disclosed transaction was $22,450.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.

Pernix Therapeutics Holdings, Inc. (Pernix) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. The Companys products include Treximet, an analgesic indicated for acute migraine; Silenor (doxepin), a prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla (desvenlafaxine extended-release tablets), for major depressive disorder. The Company distributes its generic products through wholly owned subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc. (Cypress).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.